578 related articles for article (PubMed ID: 36306803)
1. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
2. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
7. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L; Settanni CR; Varca S; Laterza L; Lopetuso LR; Napolitano D; Schiavoni E; Turchini L; Fanali C; Alfieri N; Pizzoferrato M; Papa A; Pafundi PC; Armuzzi A; Gasbarrini A; Pugliese D; Scaldaferri F
J Gastrointestin Liver Dis; 2023 Dec; 32(4):452-459. PubMed ID: 38147610
[TBL] [Abstract][Full Text] [Related]
10. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
Pintar Š; Hanžel J; Drobne D; Koželj M; Kurent T; Smrekar N; Novak G
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399583
[No Abstract] [Full Text] [Related]
11. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
Martin A; Nachury M; Peyrin-Biroulet L; Bouhnik Y; Nancey S; Bourrier A; Serrero M; Fumery M; Buisson A; Laharie D; Gilletta C; Filippi J; Allez M; Bouguen G; Roblin X; Altwegg R; Dib N; Pineton de Chambrun G; Savoye G; Carbonnel F; Viennot S; Amiot A;
J Crohns Colitis; 2020 Jul; 14(7):896-903. PubMed ID: 31930285
[TBL] [Abstract][Full Text] [Related]
14. The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
Abraham BP; Fan C; Thurston T; Moskow J; Malaty HM
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004241
[TBL] [Abstract][Full Text] [Related]
15. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
16. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
Hyams JS; Turner D; Cohen SA; Szakos E; Kowalska-Duplaga K; Ruemmele F; Croft NM; Korczowski B; Lawrence P; Bhatia S; Kadali H; Chen C; Sun W; Rosario M; Kabilan S; Treem W; Rossiter G; Lirio RA
J Crohns Colitis; 2022 Aug; 16(8):1243-1254. PubMed ID: 35301512
[TBL] [Abstract][Full Text] [Related]
18. Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
Colman RJ; Mizuno T; Fukushima K; Haslam DB; Hyams JS; Boyle B; Noe JD; D'Haens GR; Van Limbergen J; Chun K; Yang J; Denson LA; Ollberding NJ; Vinks AA; Minar P
Aliment Pharmacol Ther; 2023 Mar; 57(5):524-539. PubMed ID: 36314265
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.
Eriksson C; Rundquist S; Lykiardopoulos V; Udumyan R; Karlén P; Grip O; Söderman C; Almer S; Hertervig E; Marsal J; Gunnarsson J; Malmgren C; Delin J; Strid H; Sjöberg M; Öberg D; Bergemalm D; Hjortswang H; Halfvarson J;
Therap Adv Gastroenterol; 2021; 14():17562848211023386. PubMed ID: 34276808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
